While hypothalamic kisspeptin (KP) neurons play well-established roles in the estrogen-dependent regulation of reproduction, little is known about extrahypothalamic KP-producing (KPLS) neurons of the lateral septum. As established previously, Kiss1 expression in this region is low and regulated by estrogen receptor- and GABAB receptor-dependent mechanisms. Our present experiments on Kiss1-Cre/ZsGreen knock-in mice revealed that transgene… Continue reading Estrogen-Regulated Lateral Septal Kisspeptin Neurons Abundantly Project to GnRH Neurons and the Hypothalamic Supramammillary Nucleus
Tag: Breast Cancer
Data from all 50 states shows early onset breast cancer is on the rise in younger women: Does place of exposure matter?
Breast cancer incidence trends in U.S. women under 40 vary by geography and supports incorporating location information with established risk factors into risk prediction, improving the ability to identify groups of younger women at higher risk for early-onset breast cancer.
Virologist Treats Own Breast Cancer: Ethical?
Ethicist Art Caplan discusses ethical questions raised when virologist Beata Halassy treated her own breast cancer using experimental methods. Medscape Business of Medicine
[ASAP] Chemosensitizer Loaded NIR-Responsive Nanostructured Lipid Carriers: A Tool for Drug-Resistant Breast Cancer Synergistic Therapy
ACS Applied Bio MaterialsDOI: 10.1021/acsabm.4c01675
[Articles] Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial
This study did not reach its prespecified endpoint for darolutamide activity in patients with triple-negative breast cancer selected on the basis of immunohistochemistry for AR. Further studies selecting patients based on RNA profiling might allow better identification of tumours sensitive to anti-androgens.
[Articles] Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study
With extended follow-up, palbociclib plus exemestane with ovarian function suppression continued to show a significant benefit in progression-free survival compared with capecitabine in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer who had been previously treated with tamoxifen; however, no improvement in overall survival was seen. Given the progression-free survival benefit, the upfront use… Continue reading [Articles] Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study
Landmark atlas reveals how aging breast tissue shapes breast cancer risk
Aging is a privilege, but it also brings risks — including an increased likelihood of developing age-related diseases including cancer. Researchers have now created a landmark atlas of how healthy breast tissue ages, revealing key cellular, molecular, and genetic changes that may tip the balance toward breast cancer development.
[News] Largest trial of AI in breast cancer screening launched
The UK’s National Health Service (NHS) has launched the world’s largest prospective trial of using artificial intelligence (AI) to assess routine mammogram screenings. Nearly 700 000 women who have booked routine screenings in the UK will be invited to participate from April, 2025.
[ASAP] Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography
Discovery of isoquinoline-tethered quinazoline derivatives with enhanced HER2 inhibition over EGFR
Human epidermal growth factor receptor 2 (HER2) is a critical therapeutic target for HER2-positive or HER2-dependent cancers. While several HER2 kinase inhibitors have been identified, achieving high selectivity for HER2 over EGFR remains a significant challenge. In this study, we aimed to develop HER2-selective inhibitors with enhanced cellular activity. To improve the limited cellular activity… Continue reading Discovery of isoquinoline-tethered quinazoline derivatives with enhanced HER2 inhibition over EGFR